RESUMEN
OBJECTIVES: Based on this, the central therapeutic effects of thymol were verified in the neurotrophic pathway. METHODS: Female swiss mice were divided into four groups: control, corticosterone (Cort), thymol (Cort + thymol) and fluvoxamine (Cort + Flu). The administration of corticosterone was used to induce depressive symptoms for 23 days. After the treatment, the animals were exposed the behavioural tests, such as forced swimming test, tail suspension test, sucrose preference test, light/dark test, social interaction test, Y-maze test, plus-maze test and hole-board test. The hippocampus was also removed, and BDNF was measured by ELISA and Western blot. KEY FINDINGS: As a result, thymol and fluvoxamine were able to reverse the depressive symptoms, as well as to improve the anxious frame. The anhedonic and short-term memory was restored with the treatment. In the neurochemical tests, both thymol and fluvoxamine restored BDNF levels, improving the depressive condition. CONCLUSIONS: This work opens up new investigations aiming at the use of this molecule as a therapeutic alternative for treating depression disorders.
Asunto(s)
Antidepresivos/farmacología , Factor Neurotrófico Derivado del Encéfalo/metabolismo , Depresión/tratamiento farmacológico , Timol/farmacología , Animales , Conducta Animal/efectos de los fármacos , Corticosterona/administración & dosificación , Modelos Animales de Enfermedad , Femenino , Fluvoxamina/farmacología , Hipocampo/efectos de los fármacos , Hipocampo/metabolismo , Aprendizaje por Laberinto/efectos de los fármacos , Ratones , Regulación hacia Arriba/efectos de los fármacosRESUMEN
Introduction: Temporomandibular disorder (TMD) is the term used in Dentistry to define the structural and disorder changes affect the physiology of the masticatory system composed of TMJ and related to musculoskeletal structures. Objective: To conduct a descriptive, transversal and documentary study aiming to determine the profile of 14 TMD patients undergoing simultaneous dental and physiotherapeutic treatment at a private practice of the city of Fortaleza-Ce. Material and methods: The following instruments for the collection of the data were employed: files registering the evaluation and evolution, findings of the radiographic examinations and forms. Data were statistically analyzed through SPSS software, version 10.0. Results: Most of the sample was composed by females aged 32 years (+/-10.60) in average, mainly complaining about chronic headache, masticatory myalgia , TMJ pain, cervicalgy, otalgia, among others. The complete sample presented, at least, one pathology associated to and/or concomitant to TMD. The radiographic findings showed TMJ alterations and tooth losses. Analgesics were the most used drugs. Conclusion: TMD is a complex syndrome, with many etiologies and symptoms, aggravating and perpetuating factors, requiring multiple and even more specialized therapeutic management attempting treatment success.
RESUMEN
In past studies conducted by our group, riparin I (rip I) isolated from the green fruit of Aniba riparia presented antianxiety effects in mice, while its analogs rip II and III showed anxiolytic and antidepressant-like actions. This time around, we investigated a possible antidepressant activity of rip I using the forced swimming test (FST) and tail suspension test (TST) as predictive tests for antidepressant activity in rodents. In addition, the involvement of the monoaminergic system in this effect was also assessed. rip I was acutely administered by intraperitoneal (i.p.) and oral (p.o) routes to male mice at doses of 25 and 50 mg/kg. Results showed that rip I at both tested doses and administration routes produced a significant decrease in immobility time in FST and TST. The pretreatment of mice with prazosin (1 mg/kg, i.p., an α1 -adrenoceptor antagonist), yohimbine (1 mg/kg, i.p., an α2 -adrenoceptor antagonist), SCH23390 (15 µg/kg, i.p., a dopamine D1 receptor antagonist), sulpiride (50 mg/kg, i.p., a dopamine D2 receptor antagonist), p-chlorophenylalanine (100 mg/kg, an inhibitor of serotonin synthesis) or ritanserin (4 mg/kg, a serotonin 5-HT2(A)/2(C) receptor antagonist) blocked the anti-immobility effects elicited by rip I (50 mg/kg, p.o.) in the FST. Taken together, results indicate that rip I produces significant antidepressant-like activity in the FST and TST, and this effect seems to be dependent on its interaction with noradrenergic, dopaminergic and serotonergic systems.
Asunto(s)
Antidepresivos/química , Antidepresivos/farmacología , Conducta Animal/efectos de los fármacos , Benzamidas/farmacología , Lauraceae/química , Tiramina/farmacología , Animales , Ansiolíticos/química , Ansiolíticos/farmacología , Dopamina/farmacología , Suspensión Trasera/métodos , Masculino , Ratones , Actividad Motora/efectos de los fármacos , Norepinefrina/farmacología , Natación , Tiramina/análogos & derivadosRESUMEN
OBJECTIVES: Carvacrol (5-isopropyl-2-methylphenol) is a monoterpenic phenol which is present in the essential oil of oregano and thyme. We have investigated the behavioural effects of carvacrol in animal models of pain, such as acetic acid-induced abdominal constriction, formalin and hot-plate tests in mice. The spontaneous motor activity of animals treated with carvacrol was investigated using open-field and rotarod tests. METHODS: Carvacrol was administered orally, at single doses of 50 and 100 mg/kg while indometacin (5 mg/kg), morphine (7.5 mg/kg) and diazepam (2 mg/kg) were used as standard drugs. Naloxone (1 mg/kg) and l-arginine (150 mg/kg) were used to elucidate the possible antinociceptive mechanism of carvacrol on acetic acid-induced abdominal constriction and formalin tests. KEY FINDINGS: The results showed that carvacrol produced significant inhibitions on nociception in the acetic acid-induced abdominal constriction, formalin and hot-plate tests. In the open-field and rotarod tests carvacrol did not significantly impair the motor performance. The effect of the highest dose of carvacrol in mice in the acetic acid-induced abdominal constriction and formalin tests were not reversed by naloxone or l-arginine. CONCLUSIONS: Based on these results, it has been suggested that carvacrol presents antinociceptive activity that may not act through the opioid system nor through inhibition of the nitric oxide pathway.